https://www.selleckchem.com/pr....oducts/n-ethylmaleim
Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. In this context, novel drug combinations are needed to increase its antitumor activity. In this work, we have evaluated the efficacy of proteolysis targeting chimera (PROTAC) compounds based on BET inhibitors (BETi) to augment the activity of trastuzumab in HER2+ breast cancer models. BT474 and SKBR3 HER2+ breast cancer cell lines were used. The effects of trastuzumab and th
Like
Comment
Share
